收藏切换
Exploration of non-clinical pharmacodynamics evaluation system of ischemic stroke
收藏切换
Yan YANG1, Chun-yang ZHAO2, Kai QU1, Lei WU1, Qing-li WANG3, *, Ying PENG1, *
Acta Pharmaceutica Sinica | 2026, 61(2) : 332 - 348
Less
收藏切换
Acta Pharmaceutica Sinica | 2026, 61(2): 332-348
• Reviews •
Exploration of non-clinical pharmacodynamics evaluation system of ischemic stroke
Full
Yan YANG1, Chun-yang ZHAO2, Kai QU1, Lei WU1, Qing-li WANG3, *, Ying PENG1, *
Affiliations
  • 1Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
  • 2Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China
  • 3National Institute for Food and Drug Control, Beijing 102629, China
Published: 2026-02-12 doi: 10.16438/j.0513-4870.2025-0869
Outline
收藏切换

Ischemic stroke (IS) remains a leading cause of mortality and disability among adults worldwide, with its core pathological mechanism rooted in ischemic-hypoxic neuronal injury triggered by cerebral blood flow interruption. Current clinical treatments primarily rely on intravenous thrombolysis and endovascular thrombectomy. However, these approaches are constrained by strict therapeutic time windows (typically ≤ 4.5 h), bleeding risks in certain patients, and limited neurorestorative effects following reperfusion. Despite active development of neuroprotective agents and anti-inflammatory drugs in recent years, most have failed in clinical translation due to insufficient efficacy or safety concerns, highlighting the complexity of disease mechanisms and limitations of preclinical evaluation systems. Consequently, developing therapeutics that simultaneously address reperfusion protection and neural repair by targeting the pathological cascade of IS has emerged as a critical direction to overcome current therapeutic bottlenecks. This review synthesizes recent advances in domestic and international IS drug development in recent years, focusing on model establishment, efficacy evaluation metrics, and relevant molecular mechanisms to systematically summarize the preclinical pharmacodynamic evaluation framework for IS therapeutics. The findings provide valuable insights for optimizing preclinical evaluation systems, accelerating drug development, and expanding effective clinical treatment strategies for IS.

ischemic stroke  /  non-clinical pharmacodynamic evaluation  /  animal model  /  drug discovery  /  molecular mechanism
杨艳, 赵春阳, 渠凯, 吴镭, 王庆利, 彭英. 抗缺血性脑卒中药物非临床药效学评价体系探索. 药学学报, 2026 , 61 (2) : 332 -348 . DOI: 10.16438/j.0513-4870.2025-0869
Yan YANG, Chun-yang ZHAO, Kai QU, Lei WU, Qing-li WANG, Ying PENG. Exploration of non-clinical pharmacodynamics evaluation system of ischemic stroke[J]. Acta Pharmaceutica Sinica, 2026 , 61 (2) : 332 -348 . DOI: 10.16438/j.0513-4870.2025-0869
Year 2026 volume 61 Issue 2
317
155
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2025-0869
  • Receive Date:2025-07-23
  • Online Date:2026-09-21
  • Published:2026-02-12
Article Data
Affiliations
History
  • Received:2025-07-23
  • Revised:2025-10-10
Affiliations
    1Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
    2Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China
    3National Institute for Food and Drug Control, Beijing 102629, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2025-0869
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT